PT1169021E - Composições e métodos para o tratamento de linfoma - Google Patents

Composições e métodos para o tratamento de linfoma Download PDF

Info

Publication number
PT1169021E
PT1169021E PT00920004T PT00920004T PT1169021E PT 1169021 E PT1169021 E PT 1169021E PT 00920004 T PT00920004 T PT 00920004T PT 00920004 T PT00920004 T PT 00920004T PT 1169021 E PT1169021 E PT 1169021E
Authority
PT
Portugal
Prior art keywords
mol
compositions
methods
cholesterol
lymphoma
Prior art date
Application number
PT00920004T
Other languages
English (en)
Portuguese (pt)
Inventor
Andreas H Sarris
Fernando Cabanillas
Patricia M Logan
Clive T R Burge
James H Goldie
Murray S Webb
Mayer D Lawrence
Original Assignee
Univ Texas
Hana Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Hana Biosciences Inc filed Critical Univ Texas
Publication of PT1169021E publication Critical patent/PT1169021E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT00920004T 1999-04-01 2000-03-31 Composições e métodos para o tratamento de linfoma PT1169021E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02

Publications (1)

Publication Number Publication Date
PT1169021E true PT1169021E (pt) 2009-11-18

Family

ID=26825635

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00920004T PT1169021E (pt) 1999-04-01 2000-03-31 Composições e métodos para o tratamento de linfoma

Country Status (13)

Country Link
EP (3) EP1169021B1 (enExample)
JP (3) JP2002541088A (enExample)
AT (1) ATE442839T1 (enExample)
AU (1) AU777572B2 (enExample)
BR (1) BRPI0009448B8 (enExample)
CA (1) CA2366787C (enExample)
CY (1) CY1109641T1 (enExample)
DE (1) DE60042968D1 (enExample)
DK (2) DK1169021T3 (enExample)
ES (2) ES2524141T3 (enExample)
IL (4) IL145720A0 (enExample)
PT (1) PT1169021E (enExample)
WO (1) WO2000059473A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
EP1169021B1 (en) * 1999-04-01 2009-09-16 Hana Biosciences, Inc. Compositions and methods for treating lymphoma
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
JP2004524368A (ja) * 2001-03-27 2004-08-12 フェアーズ ファーマシューティカル リサーチ エヌ．ヴェー． 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物
EP2105135B1 (en) * 2002-05-17 2014-10-22 Celgene Corporation Pharmaceutical compositions for treating cancer
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
RU2252764C2 (ru) * 2003-03-04 2005-05-27 Российский научный центр рентгенорадиологии МЗ РФ Способ комплексного лечения лимфогранулематоза
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
BRPI0513007A (pt) * 2004-07-09 2008-04-22 Schering Ag terapia de combinação com anticorpo anti-cd20 marcado radioativamente no tratamento de linfoma de célula b
AU2005272946B2 (en) * 2004-08-10 2012-01-12 Talon Therapeutics, Inc. Compositions and methods for treating leukemia
HRP20160430T1 (hr) 2007-09-10 2016-05-20 Boston Biomedical, Inc. Nova grupa inhibitora stat3 puta i inhibitora puta matičnih stanica karcinoma
KR102449659B1 (ko) 2008-03-18 2022-09-29 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
CA2741265A1 (en) * 2008-10-24 2010-04-29 Gloucester Pharmaceuticals Cancer therapy
US9801874B2 (en) * 2012-11-20 2017-10-31 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine for therapeutic use
US20140205543A1 (en) * 2013-01-24 2014-07-24 Memorial Sloan-Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
SI26542A (sl) 2023-09-12 2025-03-31 Univerza V Ljubljani Nove liposomske formulacije in postopek za njihovo pripravo

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
EP1169021B1 (en) * 1999-04-01 2009-09-16 Hana Biosciences, Inc. Compositions and methods for treating lymphoma

Also Published As

Publication number Publication date
AU777572B2 (en) 2004-10-21
ATE442839T1 (de) 2009-10-15
JP5981214B2 (ja) 2016-08-31
BRPI0009448B1 (pt) 2018-09-11
EP2266537A3 (en) 2012-02-22
EP2266537A2 (en) 2010-12-29
BRPI0009448B8 (pt) 2021-05-25
EP1169021B1 (en) 2009-09-16
IL212390A (en) 2014-08-31
IL212389A (en) 2015-07-30
IL212389A0 (en) 2011-06-30
CA2366787A1 (en) 2000-10-12
IL145720A (en) 2011-05-31
AU4060600A (en) 2000-10-23
EP1985285A3 (en) 2009-08-12
EP1985285A2 (en) 2008-10-29
ES2524141T3 (es) 2014-12-04
HK1152246A1 (en) 2012-02-24
JP2002541088A (ja) 2002-12-03
EP2266537B1 (en) 2014-09-03
EP1169021A1 (en) 2002-01-09
WO2000059473A1 (en) 2000-10-12
ES2333400T3 (es) 2010-02-22
CY1109641T1 (el) 2014-08-13
DE60042968D1 (de) 2009-10-29
DK2266537T3 (en) 2014-12-15
JP2012158602A (ja) 2012-08-23
BR0009448A (pt) 2002-01-08
IL145720A0 (en) 2002-07-25
CA2366787C (en) 2013-03-12
IL212390A0 (en) 2011-06-30
DK1169021T3 (da) 2010-01-11
JP2015071631A (ja) 2015-04-16

Similar Documents

Publication Publication Date Title
IL212389A0 (en) Compositions comprising liposome-encapsulated vincristine for use in treating cancer
EP0955044A3 (en) Method of inhibiting bacterial or fungal growth using a complexing agent
WO1999043355A3 (en) Formulations containing oxaliplatin
SG47520A1 (en) New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
IL140710A0 (en) Pulmonary delivery of active agents
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
PL338181A1 (en) Novel chemical compounds
WO2003051275A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
GB0028323D0 (en) Tetrahydrofuran-adducted group 11 ›-diketonate complexes as source reagents for chemical vapor depostion
EP0924970A3 (en) Cleaning solution for electronic materials and method for using the same
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
TW230775B (enExample)
AU695749B2 (en) Functional terpyridine metal complexes, a process for the preparation therof and oligonucleotide conjugates with terpyridine-metal complexes
CA2052640A1 (en) Method for destroying cyst of noxious plankton
WO2000076989A3 (de) Verfahren zur umsetzung organischer verbindungen mit wasserstoffperoxid
ES2173464T3 (es) Preparacion de clorinas y bacterioclorinas con contenido en polieter.
WO1997013776A3 (fr) Nouveaux derives amines de 2', 3' didesoxyglycosides d'epipodophyllotoxine, leur procede de preparation, leur utilisation comme medicament et leur utilisation destinee aux traitements anticancereux
CA2261802A1 (en) Use of xanomeline for treating bipolar disorder
MX9801130A (es) Tiamacrolidos.
WO2001062668A3 (en) Sulfur containing compounds
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
AU5645899A (en) Plant fungus inhibiting compounds, process for their preparation, compositions containing them and their use in method for combatting plant fungi